The Unciti-Broceta Group is based at the Cancer Research UK Edinburgh Centre, part of the Institute of Genetics and Cancer at the University of Edinburgh, where Prof Unciti-Broceta established the chemistry section of the Institute in 2010.

 

The lab explores novel chemical strategies to improve the efficacy and safety of cancer treatments. This includes the discovery and development of anticancer kinase inhibitors and prodrugs that are activated by bioorthogonal reactions.

 

 

Group logo.jpg
Group logo.jpg

press to zoom
_DSC2570
_DSC2570

press to zoom
Funders2010-2014.jpg
Funders2010-2014.jpg

press to zoom
Group logo.jpg
Group logo.jpg

press to zoom
1/16

LATEST NEWS

 

NEW

NOV 2021 Check out our new biomedical application of bioorthogonal catalysis just published in Angewandte Chemie

 

 

OCT 2021 Interested in the chemistry behind approved kinase inhibitors? Check out our comprehensive perspective in Journal of Medicinal Chemistry.

 

 

SEP 2021 NXP900 (aka eCF506), discovered by our lab, a selective inhibitor of SRC and YES1, is licensed to Nuvectis Pharma.

 

 

AUG 2021 10 years of research culminates with this work, published in Cancer Research. Our most important contribution to the cancer field. Joint effort from @EdinCRC, @MRC_CRH and @CIB_CSIC!!

 

 

Follow us in

  • Twitter Classic
  • Facebook Classic